Ingrid Rayez

Associate

Florian Reinaud

Partner

59 past transactions

Fabrico SaaS

Seed Round in 2023
Fabrico is a cloud-based CMMS that manages all maintenance activities in a manufacturing facility by combining lean end-to-end maintenance methodologies. Everything required to digitalize all maintenance procedures in your plant is included in the solution. Fabrico offers preventive and reactive maintenance solutions, as well as an efficient ticketing system that allows for entire communication and compliance processes in a single plant.

GeoSpock

Series B in 2019
GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Wandercraft

Series B in 2017
Wandercraft is a pioneering company that develops and sells advanced exoskeletons designed to enable autonomous, self-balanced walking for individuals with mobility impairments. Its flagship product, Atalante, which received CE marking in 2019, is utilized in European rehabilitation hospitals to facilitate gait re-learning treatments. The company is in the process of obtaining FDA approval for its technology. Wandercraft's exoskeletons are distinguished by their realistic gait capabilities, allowing users to walk without crutches or additional aids. In addition to its rehabilitation products, the company is also working on a more agile Personal Mobility exoskeleton intended for everyday use. Wandercraft integrates expertise in algorithmics, artificial intelligence, robotics, production, and clinical practices, positioning itself as a leader in the development of innovative mobility solutions for paraplegics and individuals with myopathic conditions.

BioSerenity

Series A in 2017
BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through innovative, digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling continuous remote monitoring of patients' health data, BioSerenity aims to optimize patient pathways in cardiology, neurology, and sleep disorders. The company also collaborates with the scientific community by providing anonymized data to researchers at the Institut du Cerveau et de la Moelle épinière (ICM), thereby contributing to advancements in epilepsy research and improving future diagnostic methods.

OpenHealth Company

Private Equity Round in 2017
OpenHealth Company specializes in the real-time processing and analysis of health consumption data. The company's innovative platform collects health data from various sources, including pharmacies, outpatient medical facilities, and patient longitudinal records. By transforming this data into actionable insights, OpenHealth aims to enhance healthcare decision-making. Its services cater to a diverse clientele, including health authorities, industry stakeholders, researchers, and the general public, providing valuable information for both marketing and clinical research purposes.

Ekinops

Post in 2017
Ekinops is a company that specializes in next-generation optical transport solutions aimed at service providers and private networks globally. It offers a range of carrier-grade products, including the EKINOPS 360 platform, which is designed for metro, regional, and long-haul applications. Ekinops leverages its expertise in 10G, 100G, and 200G transmission technologies to enhance data transport capacity over various networks, including dark fiber, CWDM, DWDM, and SONET/SDH. Its solutions are engineered to optimize optical networks, enabling operators to efficiently manage data transmission and aggregation while ensuring high reliability through advanced Forward Error Correction capabilities.

Paragon Id

Post in 2016
Paragon ID specializes in identification solutions, serving diverse markets such as public transport, manufacturing, and retail. The company designs and manufactures contactless technology, including smart cards, tickets, RFID tags, and NFC solutions. With over 600 employees and manufacturing sites across the US, Europe, and Asia, Paragon ID caters to clients worldwide. As part of the Paragon Group, it generates a significant portion of its revenue from the EMEA region.

Kayentis

Venture Round in 2016
Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and Decentralized Clinical Trial solutions, focused on enhancing the efficiency and quality of data collection in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has specialized in eCOA solutions across various phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. Kayentis has adapted to the evolving clinical research landscape by offering a comprehensive suite of services aimed at supporting science-driven and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, Kayentis provides a range of adaptable tools to streamline electronic data capture, simplifying the clinical trial process for both patients and research sites.

H4D

Series B in 2016
H4D, established in 2008, focuses on bridging gaps in healthcare access due to geographic or social barriers while promoting preventive medicine and managing chronic diseases. The company is dedicated to making health checks universally accessible, ensuring that individuals, regardless of their location or social circumstances, can receive necessary healthcare services. H4D has developed a telemedicine platform that enables patients to connect with healthcare professionals remotely, particularly targeting populations in underserved areas, employees in corporate settings, the elderly in communal living situations, and students. This innovative system facilitates access to general and specialist medical advice, thus enhancing healthcare delivery and communication with local health stakeholders. H4D's commitment to integrating its health programs into broader health strategies underscores its dedication to improving overall health outcomes.

Biomodex

Seed Round in 2016
Biomodex is a medical technology company headquartered in Paris and Boston that specializes in 3D printing to create tissue-like anatomical models derived from medical images. These anatomically accurate replicas are designed to enhance physician training and patient-specific rehearsal by providing critical tactile feedback. Incorporating biomechanical and imaging properties along with fluid dynamics, Biomodex's technology is seamlessly integrated into imaging and procedural workflows. This innovative approach aims to boost the preparedness and confidence of treating physicians, thereby reducing the likelihood of surgical errors and associated medical costs.

Expway

Venture Round in 2016
Expway SA is a leading provider of wireless multicast solutions, specializing in LTE broadcast services. Founded in 2000 and headquartered in Paris, France, with additional offices in North America, South Korea, Japan, and China, the company develops a range of products aimed at network operators, mobile carriers, device manufacturers, and application developers. Its offerings include Expway Middleware, which enables devices to access LTE broadcast for streaming video content, and the Expway Broadcast Multicast Service Center, a server that facilitates simultaneous high-quality content delivery to numerous subscribers. The company also provides tools such as the Expway Broadcast Provisioning Manager for managing LTE broadcasting services, as well as compact platforms for proof-of-concept and lab evaluations. Expway's innovative solutions support the growing demand for mobile broadcasting, positioning the company at the forefront of the mobile video market.

Wandercraft

Series A in 2015
Wandercraft is a pioneering company that develops and sells advanced exoskeletons designed to enable autonomous, self-balanced walking for individuals with mobility impairments. Its flagship product, Atalante, which received CE marking in 2019, is utilized in European rehabilitation hospitals to facilitate gait re-learning treatments. The company is in the process of obtaining FDA approval for its technology. Wandercraft's exoskeletons are distinguished by their realistic gait capabilities, allowing users to walk without crutches or additional aids. In addition to its rehabilitation products, the company is also working on a more agile Personal Mobility exoskeleton intended for everyday use. Wandercraft integrates expertise in algorithmics, artificial intelligence, robotics, production, and clinical practices, positioning itself as a leader in the development of innovative mobility solutions for paraplegics and individuals with myopathic conditions.

Crocus Technology

Series E in 2015
Crocus Technology SA specializes in the development of magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company provides innovative solutions that include magnetic sensors and embedded memory technology, designed to enhance sensor data gathering and performance. Its products are utilized across various applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's offerings are characterized by their ability to execute fast read and write operations within a compact footprint, which improves the performance and security of chips used in smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature, low power consumption, and cost-effectiveness, the company enables its clients to achieve enhanced performance and increased productivity in their operations.

Zesty

Series A in 2015
Zesty Limited is a digital health company based in London, United Kingdom, that provides on-demand access to healthcare appointments through various digital platforms, including desktop, tablet, and mobile applications. Established in 2012, Zesty offers a suite of tools for healthcare providers to streamline booking and managing appointments, facilitate digital communication of medical records, and enable patients to manage their healthcare from their smartphones. The company's clients include hospitals, community providers, and general practice surgeries, who pay annual subscription fees or fees based on patient usage. Zesty aims to enhance the healthcare experience by removing barriers to common health-related tasks, such as appointment scheduling and prescription management, while empowering patients to take an active role in their care.

FittingBox

Series B in 2014
FittingBox, founded in 2006 by cousins Ariel Choukroun and Benjamin Hakoun, specializes in enhancing the customer experience of purchasing glasses through augmented reality technology. The company was inspired by a personal challenge faced by Ariel when he needed help selecting glasses due to his inability to see himself clearly in an optician's mirror. FittingBox aims to improve this process for all customers by offering digital solutions that include three-dimensional compression, face detection, and an interactive platform. This technology helps users find frames that best suit their body type and style, ultimately benefiting eyecare professionals by boosting their business.

Voluntis

Series D in 2014
Voluntis, established in 2001, specializes in developing digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. The company offers products such as Insulia, Diabeo, Oleena, and AstraZeneca, which provide automated insulin dose recommendations, patient-specific dosage suggestions, and management of side effects like hypertension and diarrhea. Voluntis collaborates with pharmaceutical companies like Bristol-Myers Squibb to co-develop digital therapeutics for oncology. With a patient-centric approach, Voluntis aims to enhance medical practices and improve healthcare system efficiency through secure, collaborative, and innovative digital health solutions.

Maeglin Software

Venture Round in 2012
Maeglin Software specializes in the development and marketing of innovative mobile Value Added Services for the telecommunications industry. The company focuses on creating peer-to-peer software solutions that facilitate the sharing of online mobile content and enable users to access and share backed-up contacts, pictures, videos, and documents via web and mobile internet. By prioritizing user data protection and cost control, Maeglin Software aims to enhance the mobile experience and empower individuals to manage their mobile lives more effectively.

Aldebaran Robotics

Series C in 2011
Aldebaran Robotics, established in 2005 and headquartered in Paris, France, specializes in the design, manufacture, and sale of autonomous humanoid robots. Their product portfolio includes NAO, a 58-cm tall companion robot capable of moving, recognizing, hearing, and speaking to humans; Pepper, a social robot that engages in conversation, recognizes individuals, responds to emotions, and navigates autonomously; and Romeo, a 140-cm humanoid robot designed for research into assistance for the elderly and those with mobility challenges, featuring advanced capabilities such as door opening, stair climbing, and object manipulation. The company's robots are employed in entertainment, reception, assistance, home care, and autism therapy applications.

Cytheris

Series D in 2010
Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

IntegraGen

Venture Round in 2010
IntegraGen is a French biotechnology company located in the Genopole life science park in Evry, near Paris. The company specializes in the development of genetic biomarkers and leverages its proprietary technology platforms to provide genomics services to the pharmaceutical industry, biotechnology firms, and research organizations. IntegraGen offers a range of services, including clinical research, bioinformatics, and bioanalysis, as well as solutions for agrigenomics and microbiologic research. With its unique intellectual property and access to extensive sample libraries, IntegraGen aims to advance the understanding and treatment of central nervous system and metabolic diseases.

OMNIlife science

Venture Round in 2010
OMNIlife science, Inc. specializes in the design, manufacture, and distribution of orthopedic devices, focusing on joint replacement solutions. Founded in 1999 and headquartered in East Taunton, Massachusetts, the company offers a range of products, including orthopedic implants for knees and hips, as well as advanced robotic navigation technology known as OMNINAV, which enhances the precision of total knee surgeries tailored to individual patients. The company serves a diverse international market, including regions such as South Africa, Switzerland, Turkey, and several European countries, distributing its products through various distributors. OMNIlife science operates as a subsidiary of Orthopaedic Synergy, Inc.

FittingBox

Venture Round in 2009
FittingBox, founded in 2006 by cousins Ariel Choukroun and Benjamin Hakoun, specializes in enhancing the customer experience of purchasing glasses through augmented reality technology. The company was inspired by a personal challenge faced by Ariel when he needed help selecting glasses due to his inability to see himself clearly in an optician's mirror. FittingBox aims to improve this process for all customers by offering digital solutions that include three-dimensional compression, face detection, and an interactive platform. This technology helps users find frames that best suit their body type and style, ultimately benefiting eyecare professionals by boosting their business.

Santen Pharmaceutical

Series D in 2009
Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.

Radio Systemes Ingenierie

Series D in 2009
Radio Systemes Ingenierie S.A. provides wireless communication systems. It offers Visioguard, a wireless alarm system that provide remote video monitoring, local monitoring with a TV or a monitor, integrated Internet-server, and emails with attached video-files. The company was founded in 2000 and is based in Strasbourg, France.

Anevia

Series B in 2009
Anevia is a software company specializing in IPTV and over-the-top (OTT) video solutions, aimed at delivering live TV and video on demand (VOD) services across various devices, including TVs, PCs, and mobile devices. With a presence in over 70 countries and more than 1,000 deployments, Anevia supports millions of users and provides access to over 25,000 live channels. The company's offerings include advanced video compression, multiscreen IPTV headends, Cloud DVRs, and content delivery network (CDN) solutions, enabling the seamless delivery of high-quality video content, including 4K UHD, to diverse audiences. Anevia's technology is utilized by prominent telecom operators, broadcast service providers, and businesses in sectors such as hospitality and healthcare, reflecting its significant impact on the global video services market.

Stantum

Series B in 2009
Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Novaled

Series C in 2009
Novaled AG is a leading technology provider specializing in organic light-emitting diode (OLED) technologies. Founded in March 2003 and headquartered in Dresden, Germany, the company develops high-efficiency, long-lifetime OLED structures, leveraging its expertise in synthetic and analytical chemistry. Novaled offers comprehensive solutions for the organic electronic markets, including customized OLED products and services used in various applications, such as televisions and mobile phones. The company has established long-term partnerships with major players in the OLED industry and holds a robust intellectual property portfolio, with over 500 patents granted or pending. Additionally, Novaled has branch offices in Asia to support its global operations.

cacaoTV

Seed Round in 2008
Introduction to cacaoTV cacaoTV is a software that allows to view a streaming audio video media (i.e. TV channels) based on Peer to Peer (P2P) technology. cacaoTV works by using P2P technology, thus everyone when viewing media with cacaoweb client, the viewers upload content at the same time the programs are downloaded and viewed. cacaoweb creates a local stream on localhost and that stream is then read by Windows Media Player, Real Player or other media players. Since all viewers will upload content when viewing media, everyone becomes a broadcaster (server) without the cost of traditional streaming. And hence, the more users are online, the faster the programs can be loaded. And it will automatically find different connection nodes and download stream data from the nearest location (nodes). The good thing is, stream data is buffering in the memory, not on the hard disk. Channel Availability and Reliability Currently, most of the media contents are TV channels from the USA, and it includes some subscribers-based international channel such as HBO, ESPN, National Geographic and etc. Lately there are some independent channels that broadcast selective collection of media, such as latest blockbuster movies, collection of movies from a celebrity, or whole series of a drama. This kind of channels is created by individual viewers. There are also some radio channels available. Ease of Use and Speed of cacaoTV Just download cacaoweb and install it, and you’re ready to jump on the bandwagon of P2P TV. cacaoweb is able to work perfectly and stream smoothly without any configuration.

Crocus Technology

Series B in 2008
Crocus Technology SA specializes in the development of magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company provides innovative solutions that include magnetic sensors and embedded memory technology, designed to enhance sensor data gathering and performance. Its products are utilized across various applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's offerings are characterized by their ability to execute fast read and write operations within a compact footprint, which improves the performance and security of chips used in smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature, low power consumption, and cost-effectiveness, the company enables its clients to achieve enhanced performance and increased productivity in their operations.

TxCell

Series B in 2008
TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.

EI-Technologies

Venture Round in 2008
EI-Technologies is a Paris-based IT consulting and internet software development company founded in 1994. It offers services including Salesforce solutions, workplace solutions under the brand EI-Workplace, and training on Salesforce technologies through EI-Institut. The company specializes in integrating digital technology to improve and optimize clients' technological and cloud-based processes. EI-Technologies is known for its expert teams and high-quality management, providing end-to-end solutions tailored to clients' strategic goals.

Santaris Pharma

Series C in 2007
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Wirecom Technologies

Series B in 2007
WIRECOM Technologies is a French company with state-of-the-art technology and an experience of over 10 years. Committed to sustainable development and the fight against global warming, WIRECOM Technologies designs and develops solutions to optimise energy efficiency in buildings and residences

Iwedia

Series D in 2007
Iwedia Technologies S.A. is a French company established in 2004 and headquartered in Rennes. It specializes in providing software solutions for connected audiovisual digital terminals, focusing on the entire digital image chain. The company offers a range of services, including software engineering, system integration, user experience design, and product development. Iwedia's expertise enables clients to access customized software components and engineering services tailored for connected TV devices, positioning the company as a key player in the audiovisual technology sector.

Aldebaran Robotics

Series A in 2007
Aldebaran Robotics, established in 2005 and headquartered in Paris, France, specializes in the design, manufacture, and sale of autonomous humanoid robots. Their product portfolio includes NAO, a 58-cm tall companion robot capable of moving, recognizing, hearing, and speaking to humans; Pepper, a social robot that engages in conversation, recognizes individuals, responds to emotions, and navigates autonomously; and Romeo, a 140-cm humanoid robot designed for research into assistance for the elderly and those with mobility challenges, featuring advanced capabilities such as door opening, stair climbing, and object manipulation. The company's robots are employed in entertainment, reception, assistance, home care, and autism therapy applications.

Citilog

Series D in 2006
Citilog S.A. specializes in video-based real-time monitoring and surveillance solutions tailored for the transportation sector. Founded in 1997 and headquartered in Arcueil, France, the company develops advanced systems that enable rapid incident detection on highways, bridges, and tunnels, significantly enhancing safety and operational efficiency. Its product lineup includes Automatic Incident Detection systems, traffic data collection tools, and various video management platforms, such as MediaManager. Additionally, Citilog offers specialized sensors for traffic presence and queue detection, license plate recognition, and the identification of vehicles carrying hazardous materials. These solutions are crucial for road transportation applications and cater to smart city initiatives. Citilog distributes its products through value-added resellers and distributors globally and maintains additional offices in Bala Cynwyd, Pennsylvania; Valencia, Spain; and Wanchai, Hong Kong. As of early 2016, Citilog operates as a subsidiary of Axis Communications AB.

Crocus Technology

Series A in 2006
Crocus Technology SA specializes in the development of magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company provides innovative solutions that include magnetic sensors and embedded memory technology, designed to enhance sensor data gathering and performance. Its products are utilized across various applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's offerings are characterized by their ability to execute fast read and write operations within a compact footprint, which improves the performance and security of chips used in smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature, low power consumption, and cost-effectiveness, the company enables its clients to achieve enhanced performance and increased productivity in their operations.

NEMOPTIC

Series D in 2006
Nemoptic, an epaper display company, designs and manufactures superior-quality bistable liquid crystal displays (LCD) modules highly suitable for consumer and professional mobile devices.

Santen Pharmaceutical

Post in 2006
Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.

Iwedia

Series C in 2006
Iwedia Technologies S.A. is a French company established in 2004 and headquartered in Rennes. It specializes in providing software solutions for connected audiovisual digital terminals, focusing on the entire digital image chain. The company offers a range of services, including software engineering, system integration, user experience design, and product development. Iwedia's expertise enables clients to access customized software components and engineering services tailored for connected TV devices, positioning the company as a key player in the audiovisual technology sector.

Wirecom Technologies

Series A in 2006
WIRECOM Technologies is a French company with state-of-the-art technology and an experience of over 10 years. Committed to sustainable development and the fight against global warming, WIRECOM Technologies designs and develops solutions to optimise energy efficiency in buildings and residences

Novaled

Series B in 2005
Novaled AG is a leading technology provider specializing in organic light-emitting diode (OLED) technologies. Founded in March 2003 and headquartered in Dresden, Germany, the company develops high-efficiency, long-lifetime OLED structures, leveraging its expertise in synthetic and analytical chemistry. Novaled offers comprehensive solutions for the organic electronic markets, including customized OLED products and services used in various applications, such as televisions and mobile phones. The company has established long-term partnerships with major players in the OLED industry and holds a robust intellectual property portfolio, with over 500 patents granted or pending. Additionally, Novaled has branch offices in Asia to support its global operations.

Graitec Group

Series C in 2005
Graitec Group is a software development company specializing in Building Information Modeling (BIM) and computer-aided design (CAD) solutions for the architecture, engineering, and construction (AEC) industry. Founded in 1986, Graitec operates across 29 offices in 12 countries, serving over 40,000 construction professionals globally. The company is recognized as an Autodesk Platinum Partner and provides a comprehensive range of software, including Graitec Advance, which streamlines the structural design and construction documentation process. This technology automates key tasks such as engineering design, structural analysis, member optimization, detailing, and fabrication. Graitec's solutions enhance collaboration among project stakeholders, improve communication, and enable efficient project management through features like automatic document creation and project tracking. The firm's focus on innovation and quality positions it as a leader in delivering high-performance BIM solutions that meet the evolving demands of the construction industry.

Iwedia

Series B in 2005
Iwedia Technologies S.A. is a French company established in 2004 and headquartered in Rennes. It specializes in providing software solutions for connected audiovisual digital terminals, focusing on the entire digital image chain. The company offers a range of services, including software engineering, system integration, user experience design, and product development. Iwedia's expertise enables clients to access customized software components and engineering services tailored for connected TV devices, positioning the company as a key player in the audiovisual technology sector.

Ipracom

Series B in 2005
Ipracom SA is a technology company based in Massy, France, specializing in software solutions for personal digital assistants (PDAs) and smartphones. The company provides products that facilitate peer-to-peer communication, allowing users to connect their mobile devices to personal computers for file access and email management. Ipracom also develops software tailored for specific industry applications. Its notable clientele includes major telecommunications companies such as Orange, Bouygues Telecom, and Smart Communications. As of November 2007, Ipracom operates as a subsidiary of Maeglin Software.

Zealand Pharma

Venture Round in 2005
Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company has a growing proprietary pipeline that includes several clinical candidates such as glepaglutide for short bowel syndrome and dasiglucagon for diabetes management and congenital hyperinsulinism. Zealand's first developed medicine, lixisenatide, is a once-daily GLP-1 analogue for Type 2 diabetes, marketed globally outside the US. The company has established collaborations with major pharmaceutical partners, including Sanofi, Helsinn Healthcare, and Boehringer Ingelheim, enhancing its product offerings and expanding its reach in the market. Zealand Pharma is committed to advancing innovative therapies, with multiple projects in various stages of clinical development and preclinical research.

Kuros Biosciences

Post in 2005
Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Radio Systemes Ingenierie

Series C in 2004
Radio Systemes Ingenierie S.A. provides wireless communication systems. It offers Visioguard, a wireless alarm system that provide remote video monitoring, local monitoring with a TV or a monitor, integrated Internet-server, and emails with attached video-files. The company was founded in 2000 and is based in Strasbourg, France.

Santen Pharmaceutical

Series B in 2004
Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.

RocTool

Venture Round in 2004
RocTool S.A. is a technology and manufacturing solutions provider based in Le Bourget du Lac, France, specializing in induction heating systems, tooling hardware, and engineering services. The company develops advanced solutions for injection and compression molding, targeting industries such as automotive, consumer electronics, aerospace, and medical sectors. RocTool's innovative technologies, including Induction Dual Heating (IDH™) and HD Plastics™, enhance manufacturing processes by reducing cycle times and improving product quality. Additionally, the company offers a range of products, including generators, cooling units, and design services, while also licensing its patented technologies to various industries. RocTool operates internationally, with a presence in North America, Japan, Taiwan, and Germany, and is committed to adapting its technologies to meet the evolving needs of its clients.

Santen Pharmaceutical

Post in 2003
Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.

TheraDiag

Series B in 2003
TheraDiag is a France-based company specializing in the development, manufacturing, and marketing of in-vitro diagnostic products. Founded in 1986 and headquartered in Marne La Vallée, the company offers a range of diagnostic tools, including reagents for autoimmune and infectious diseases, as well as fertility tests. Notable products include IMMUNO-TROL, a quality control tool; various instruments for disease testing; and the SQA-V semen analyzer. TheraDiag also provides advanced instrumentation such as the Theralis platform, which integrates immunofluorescence and ELISA technologies, and the FIDIS platform for laboratory analysis. Additionally, the company offers therapeutic drug monitoring services for chronic inflammatory diseases and LISA tracker, a tool designed for monitoring biotherapies.

Teem Photonics

Venture Round in 2003
Teem Photonics S.A. is a manufacturer based in Meylan, France, specializing in passively Q-switched microlasers and photonics integrated circuits utilizing ion exchange technology. The company's Q-switched microlasers are known for their distinctive capabilities of generating sub-nanosecond, high peak power pulses from compact packages at elevated repetition rates. Teem Photonics also provides a range of products, including infrared, green, and ultraviolet lasers, as well as three-dimensional microfabrication solutions. Their offerings cater to diverse applications such as biomedical uses, marking, sensing, material processing, and advanced optical systems. Additionally, the company develops custom optical devices and solutions for silicon-photonics connections, along with comprehensive optical design, testing, assembly, packaging, and technical support services. Teem Photonics, founded in 1998, maintains a global presence with offices across Europe, the Asia-Pacific region, North America, and Mexico.

Kuros Biosciences

Series A in 2002
Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Drug Abuse Sciences

Series A in 2001
Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.

TheraDiag

Series A in 2000
TheraDiag is a France-based company specializing in the development, manufacturing, and marketing of in-vitro diagnostic products. Founded in 1986 and headquartered in Marne La Vallée, the company offers a range of diagnostic tools, including reagents for autoimmune and infectious diseases, as well as fertility tests. Notable products include IMMUNO-TROL, a quality control tool; various instruments for disease testing; and the SQA-V semen analyzer. TheraDiag also provides advanced instrumentation such as the Theralis platform, which integrates immunofluorescence and ELISA technologies, and the FIDIS platform for laboratory analysis. Additionally, the company offers therapeutic drug monitoring services for chronic inflammatory diseases and LISA tracker, a tool designed for monitoring biotherapies.

6Wind

Seed Round in 2000
6WIND S.A. is a high-performance networking software company specializing in the design and development of solutions for the networking and telecommunications sectors. Founded in 2000 and headquartered in Montigny-le-Bretonneux, France, with additional offices in the United States, China, Japan, and South Korea, 6WIND provides a range of products, including network function virtualization, software-defined networking, and data center solutions. Key offerings include 6WINDGate, a packet processing software that facilitates the large-scale deployment of high-performance infrastructure networks, and the 6WIND Virtual Accelerator, which enhances virtual switching capabilities. The company also offers Turbo Router software for bare metal and virtual environments, as well as secure VPN solutions for data center interconnection. 6WIND's software solutions enable service providers, cloud providers, and enterprises to replace costly hardware with efficient software, enhancing operational performance and addressing time-to-market challenges in various networking applications.

Santen Pharmaceutical

Post in 2000
Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.